Table 1.

Treatment of active and adoptive transfer EAE with BZ194

Treatment	Number of analysed animals	Disease onset(days p.i.: active EAE; h p.t.: adoptive transfer EAE)	Disease duration (days: active EAE, hours: adoptive transfer EAE)	Max. mean clinical score	Clinical disease index	Max. body weight loss (%)a	Incidence (%)	Mortality (%)
Active EAE	Treatment Days 0–14
BZ194	17	11 ± 0*	4.7 ± 0.6*	1.8 ± 0.1*	4.4 ± 3.7*	21 ± 11*	77	0
Nicotinic acid	5	10 ± 0	6 ± 0	3.9 ± 0.8	11.8 ± 3.6	47 ± 6	100	40
Vehicle	16	10 ± 0	6 ± 0	3.4 ± 0.4	11.9 ± 3	29 ± 0	100	33
Active EAE	Treatment Days 8–14
BZ194	5	11*	5*	1.7*	4.8 ± 2.6*	20*	80	0
Vehicle	5	10	6	3.3	11.4 ± 0.5	32	100	0
Adoptive transfer EAE preventive	Treatment Days 0–4
BZ194	22	84 ± 14*	138 ± 7*	1.6 ± 0.3*	5.1 ± 3.6*	12 ± 5*	82	0
Nicotinic acid	10	64 ± 22	168 ± 0	3.1 ± 0.1	12.6 ± 6.1	18 ± 1	100	0
Vehicle	22	67 ± 13	161 ± 11	3.2 ± 0.2	11.3 ± 7.2	17 ± 4	100	0
Untreated	8	67 ± 17	165 ± 5	3.0 ± 0.5	12.5 ± 6.1	20 ± 3	100	0
Adoptive transfer EAE therapeutic	Treatment Days 3–5
BZ194	8	75 ± 2	43 ± 16*	1.9 ± 0.4	5 ± 1.5*	13 ± 3	100	0
Vehicle	8	72 ± 0	60 ± 16	2.1 ± 0.2	7.5 ± 1.6	13 ± 5	100	0

Preventive treatment of active EAE (Days 0–14 post injection): three independent experiments with BZ194 or vehicle treatment, one experiment with nicotinic acid. Treatment of active EAE during the effector phase (Days 8–14): one experiment with BZ194 and one experiment with vehicle. Adoptive transfer EAE (preventive treatment: Days 0–4): five independent experiments for BZ194 or vehicle treatment and three experiments with nicotinic acid application or untreated controls; two experiments with BZ194 or vehicle treatment for the therapeutic protocol (Days 3–5). Clinical disease index: cumulative clinical score over the entire disease course/rat.

a Maximal body weight loss: maximal body weight loss compared to the time of injection.

*P-value at least <0.05.